Study To Check The Analgesic And Anti-Inflammatory Effects Of Atorvastatin In Patients Undergoing Abdominal Surgery

• Status: Unknown status
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is planned to check the analgesic and anti-inflammatory properties of Atorvastatin in patients who will be undergoing abdominal surgery under spinal anesthesia. The investigators intend to monitor the analgesic requirements, the rate of wound healing and the inflammatory markers in this trial.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: B. J. Medical College, Pune
• Treatments: Analgesics; Anti-Inflammatory Agents; Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

1. Male or female patients aged 25-55 years

2. Patients who will be undergoing abdominal surgery under spinal anaesthesia

3. Patients who will undergo non-bowel abdominal surgery with an abdominal incision

4. Understands and agrees to comply with all study procedures including the daily treatments and follow-up visits

5. Able to understand and is voluntarily willing to sign an informed consent form for this study

6. Weight between 50 and 120 kg

Exclusion Criteria:

1. Bowel surgery or surgery under general anaesthesia

2. Any emergency operations

3. Surgery in patients in whom the chances of infection are very high. Example peritonitis, cystitis, appendical abscess, perforations, etc

4. Laparoscopic Surgery

5. Pregnant or nursing, or with the ability to become pregnant and not using an accepted form of birth control

6. Any active Cancer

7. Uncontrolled diabetes mellitis

8. Untreated hypertension

9. Psychotic disorder(s), dementia, mental retardation, or other organic mental disorders (subjects who are not mentally and physically able to personally consent for participation in this study are not eligible)

10. Any other (including acute) condition, which in the opinion of the investigator, is likely to cause non-compliance or significantly impact treatment outcomes

11. Sensitivity to the study drug or its components